Research Interests
Our laboratory conducts translational studies of hematologic disease. Using heparin induced thrombocytopenia (HIT) as a model disease, we apply in vitro, ex-vivo and in vivo approaches to uncover disease mechanisms, model disease and apply discoveries to patient care. Beyond HIT, our laboratory is investigating biomarkers of venous thrombosis and HIT, complement's role in other immune-complex disorders and mechanisms of classical pathway regulation.
Selected Grants
The role of cerebrospinal fluid complement activation in delirium and post-intensive care unit long-term cognitive impairment
ResearchAdvisor · Awarded by National Institutes of Health · 2024 - 2029Mid-Atlantic praGmatic NETwork for Inclusive Clinical trials in emergency care (MAGNETIC)
ResearchCollaborator · Awarded by National Institute of Neurological Disorders and Stroke · 2023 - 2028Stimulating Access to Research in Residency (StARR) - NHLBI
Inst. Training Prgm or CMEPreceptor · Awarded by National Heart, Lung, and Blood Institute · 2018 - 2028ALEXION Study ITP Translational Study
ResearchPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2022 - 2027Characterization of a Novel E. coli Type III Secretion System Associated with Increased Patient Mortality
ResearchAdvisor · Awarded by National Institutes of Health · 2022 - 2027aHUS Study LNP023/Novartis. A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult aHUS patients who are naive to complement inhibitor therapy.
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2022 - 2027Complement activating properties of anti-Sm/RNP antibodies in SLE
ResearchCollaborator · Awarded by Department of Defense · 2024 - 2026Hematology & Transfusion Medicine (T32)
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Institutes of Health · 1975 - 2026An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombocytopenic purpura.
Clinical TrialPrincipal Investigator · Awarded by Sanofi US · 2023 - 2026T-TAS 01 HD Chip
ResearchPrincipal Investigator · Awarded by Hikari Dx, Inc. · 2024 - 2025Comparative studies of complement responses to ICs
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2023 - 2025Novel development ofan acoustofluidic device for targeted antibody removal in pediatric organ transplan rejection
ResearchCollaborator · Awarded by National Institutes of Health · 2021 - 2025MOMENTA MOM-M281-006
Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2022 - 2025Complement and Thrombosis in HIT
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2020 - 2024Duke CTSA (TL1) Year 5
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2018 - 2024Unified Program for Therapeutics in Children
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2019 - 2024Proteomic Determination of Complement Activation in Postoperative Delirium
ResearchAdvisor · Awarded by University of Washington · 2023 - 2024An Acoustofluidic Device for Biocompatible Platelet Separation
ResearchCo Investigator · Awarded by Ascent Bio-Nano Technologies, Inc. · 2022 - 2024Acoustic Device to Prevent Antibody Mediated Organ Transplant Failure
ResearchCollaborator · Awarded by Hartwell Foundation · 2019 - 2023Role of Complement Receptors in cellualr activation by HIT immune complexes
ResearchPrincipal Investigator · Awarded by American Society of Hematology · 2021 - 2022Platelet Kinetics in Acute Thrombus Formation in Healthy and VTE Patients
FellowshipMentor · Awarded by Society for Academic Emergency Medicine · 2019 - 2022Variability in neutrophil activation
ResearchMentor · Awarded by National Institutes of Health · 2020 - 2022Complement and CR2/CD21 in the Immune Pathogenesis of HIT(R01)
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2018 - 2022Defining the role of therapeutic plasma exchange in heparin induced thrombocytopenia
ResearchMentor · Awarded by Hemophilia & Thrombosis Research Society · 2017 - 2020An Acoustofluidic Device for Biocompatible Platelet Separation
ResearchCo Investigator · Awarded by Ascent Bio-Nano Technologies, Inc. · 2018 - 2020Biological Significance of Protamine/Heparin Antibodies
ResearchMentor · Awarded by National Institutes of Health · 2015 - 2020Probing the heparin structural elements for high risk of heparin-induced thrombocytopenia (HIT)
ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2013 - 2019Duke-UNC Clinical Hematology and Transfusion Research Career Development Program
ResearchMentor · Awarded by National Institutes of Health · 2006 - 2019Probing the heparin structural elements for high risk of heparin-induced thrombocytopenia (HIT)
ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2016 - 2018Clinical Study Protocol for External Performance Evaluation of INNOVANCE Heparin on BCS XP¿Method Comparison
Clinical TrialPrincipal Investigator · Awarded by Siemens Healthcare Diagnostics · 2016 - 2018Clinical Study Protocol for External Performance Evaluation of INNOVANCE Heparin on BCS XP, Method Comparison
ResearchPrincipal Investigator · Awarded by Siemens Healthcare Diagnostics · 2017 - 2017Cellular Basis of HIT Immune Response in Cardiac Surgery
ResearchMentor · Awarded by Children's Hospital of Philadelphia · 2012 - 2017Biological Significance of Protamine/Heparin Antibodies
ResearchMentor · Awarded by Hemostasis & Thrombosis Research Society · 2015 - 2015Modeling the spectrum of HIT pathobiology
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2012 - 2014Biological Significance of Protatmine/Heparin Antibodies
FellowshipPrincipal Investigator · Awarded by National Institutes of Health · 2013 - 2014Clinical Significance of protamine/heparin antibodies after CPB
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2011 - 2014Thrombosis and Hemostasis Centers Research and Prevention Network
ResearchConsultant · Awarded by Centers for Disease Control and Prevention · 2002 - 2013Immune Dysregulation in HIT
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2006 - 2012Rare Thrombotic Diseases Clinical Research Network
ResearchCo Investigator · Awarded by National Institutes of Health · 2004 - 2010Pathogenesis of Thrombosis in HIT
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1999 - 2004External Relationships
- ABCAM PLC
- Alexion Pharmaceuticals, Inc. a subsidiary of AstraZeneca
- Annexon
- AstraZeneca
- Biokit
- Janssen Research & Development
- Sanofi
- Veralox therapeutics
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.